A microscopy image revealing the structure of authentic reservoir clones (ARCs) – HIV-infected immune cells that evade detection – was published today, February 24, 2026, alongside a study detailing a new method for isolating and cultivating these cells in a laboratory setting. Researchers at Weill Cornell Medicine, Rockefeller University, and collaborating institutions announced the breakthrough, published in the journal Nature, as a critical step toward a functional cure for HIV.
For decades, a major obstacle in HIV research has been the inability to directly study the cells where the virus lies dormant, known as the viral reservoir. HIV integrates its genetic material into the DNA of CD4+ T cells, where it can remain inactive and invisible to the immune system and antiviral therapies. While antiretroviral therapies can suppress the virus to undetectable levels in the blood, they cannot eliminate these hidden reservoirs, requiring patients to capture medication for life.
The new study overcomes the challenge of isolating these extremely rare cells – estimated to occur at a rate of one in a million – and successfully growing them in the lab. “By isolating ARCs, we can now directly interrogate how they survive and how to eliminate them,” said Dr. Brad Jones, associate professor of immunology in medicine at Weill Cornell Medicine, and senior author of the study. The research was co-led by Dr. Isabella Ferreira, a postdoctoral associate, and Alberto Herrera, a PhD candidate, both in Dr. Jones’s lab.
Researchers collected the rare cells from study participants living with HIV. The ability to cultivate these “authentic reservoir clones” (ARCs) provides a unique opportunity to understand the mechanisms that allow them to persist despite the body’s immune defenses. The study suggests that some ARCs may be more vulnerable to immune destruction than previously understood, opening avenues for therapeutic intervention.
“We discovered that finding a needle in a haystack is not always impossible,” Dr. Jones stated. “It just takes a team effort.” The findings indicate that the virus, when dormant within the CD4+ T cell, effectively hides from the immune system. Antiviral therapies, while highly effective at suppressing viral replication, are unable to eradicate the virus due to the fact that of these persistent ARCs, which allow the virus to rebound if treatment is stopped.
The research team’s success in isolating and growing ARCs represents a significant advancement in the field. Further investigation into the characteristics of these cells is expected to inform the development of strategies aimed at targeting and eliminating the viral reservoir, potentially leading to a cure for HIV. Weill Cornell Medicine has not announced a timeline for clinical trials based on these findings.
